Introduction
The U.S. pharmaceutical supply chain has a new warning signal.
The API Innovation Center has launched the National Fragility Index, which it describes as the first U.S. benchmark specifically designed to measure structural fragility across pharmaceutical supply chains. Its initial analysis found that more than 550 million prescriptions filled in 2023 involved medicines classified as having High or Severe supply-chain fragility. GlobeNewswire
That number does not mean 550 million prescriptions were unavailable or experienced shortages. It measures exposure to structural vulnerabilities in the supply chain.
That distinction is crucial.
The new benchmark attempts to identify where the pharmaceutical system is most dependent on fragile manufacturing and sourcing structures before those weaknesses turn into an actual shortage.
For hospitals, pharmacies, policymakers and drug manufacturers, that could make the National Fragility Index an important tool for deciding where investment is most urgently needed.
Background and Context
The modern pharmaceutical supply chain is remarkably global.
A medicine consumed by an American patient may involve raw materials from one country, an active pharmaceutical ingredient manufactured in another, formulation and finishing somewhere else, and distribution through a network of U.S. wholesalers and pharmacies.
That structure can be efficient.
It can also be vulnerable.
A disruption at any major point can affect the availability of a medicine even when the final product is manufactured in the United States.
The problem became impossible to ignore during the COVID-19 pandemic.
Factories closed. Transportation networks were disrupted. Demand shifted suddenly. Hospitals struggled to obtain certain medicines and medical products.
But pharmaceutical supply-chain fragility did not begin with COVID-19.
The underlying issues include concentrated manufacturing, dependence on overseas suppliers, limited production capacity for certain active pharmaceutical ingredients, quality problems at manufacturing facilities and economic incentives that can discourage investment in lower-margin generic medicines.
The API Innovation Center has been working on this broader issue for several years. Its March 2026 analysis argued that the U.S. lacked a consistent way to identify and quantify pharmaceutical supply-chain fragility across individual medicines. Herald-Whig
The new National Fragility Index is designed to fill that gap.
Latest Update: New Benchmark Puts Pharmaceutical Fragility on a Scale
The API Innovation Center launched the National Fragility Index on October 6, 2026.
The organization describes it as the first benchmark designed to measure and track structural fragility across U.S. pharmaceutical supply chains. GlobeNewswire
The index goes down to individual drug product codes, allowing researchers and policymakers to examine vulnerabilities at a much more granular level than a broad industry-wide assessment.
That matters because “the pharmaceutical supply chain” is not one supply chain.
It is thousands of interconnected supply chains.
One medicine might have multiple manufacturers and diversified sources.
Another might depend on a small number of producers or a concentrated upstream supply base.
Treating both products as equally resilient would hide the real risk.
The National Fragility Index attempts to make those differences visible.
The 550 million prescription figure
The most attention-grabbing finding is that more than 550 million prescriptions filled in 2023 involved medicines classified as having High or Severe supply-chain fragility. GlobeNewswire
Again, that figure should not be interpreted as 550 million prescriptions being unavailable.
It represents prescriptions associated with medicines that APIIC’s methodology classifies as having significant structural vulnerabilities.
That makes the statistic potentially more useful as a risk indicator than a shortage count.
It answers a different question:
How much of America’s medicine consumption is connected to supply chains that could be vulnerable to disruption?
The answer appears to be substantial.
How Pharmaceutical Supply-Chain Fragility Happens
Supply-chain fragility can develop for several different reasons.
Supplier concentration
If only a small number of manufacturers produce an ingredient or finished medicine, a disruption at one facility can have an outsized effect.
Geographic concentration
When critical production is concentrated in a particular country or region, geopolitical events, natural disasters or trade restrictions can create systemic risk.
Limited manufacturing capacity
Some medicines operate with little spare capacity.
That means there may be no easy way for another manufacturer to quickly increase production when demand rises or an existing supplier fails.
Low-margin economics
Many generic medicines are inexpensive.
That can make it difficult for manufacturers to justify maintaining redundant factories, extra production lines or large inventories solely as insurance against a future disruption.
Quality failures
Manufacturing-quality problems can shut down facilities or trigger recalls.
Because pharmaceutical production is highly regulated, a plant cannot simply continue operating if it cannot meet required standards.
The result can be a shortage that begins with a manufacturing-quality issue rather than a lack of raw materials.
Expert Insights or Analysis
The most important contribution of the new benchmark may be that it changes the conversation from reaction to measurement.
For years, policymakers have often focused on pharmaceutical shortages after they become visible.
A drug disappears from pharmacy shelves.
Hospitals start rationing inventory.
The FDA lists the product as being in shortage.
Manufacturers announce production problems.
At that point, the system is already under stress.
A fragility index offers the possibility of identifying vulnerabilities earlier.
Think of it like a stress test for pharmaceuticals.
Instead of asking only:
“Is this medicine currently in shortage?”
policymakers can ask:
“How likely is this medicine to become difficult to supply if something goes wrong?”
That is a much more strategic question.
It also changes how investment could be allocated.
Not every medicine needs the same degree of redundancy.
A widely manufactured product with multiple domestic and international suppliers may not need major intervention.
A critical medicine with highly concentrated upstream production could require targeted investment.
The value of the benchmark is therefore not simply the ranking itself.
It is the possibility of using consistent measurements to prioritize action.
From Drug Shortages to Supply-Chain Risk
Drug shortages are often treated as isolated events.
A manufacturer stops producing a medicine.
A factory experiences a quality problem.
Demand unexpectedly increases.
A supplier runs into trouble.
But these events can reveal deeper structural weaknesses.
If one factory closes and another manufacturer can immediately increase production, the supply chain is resilient.
If one factory closes and no other producer can replace its output, the system is fragile.
That distinction is fundamental.
A resilient supply chain has alternatives.
A fragile supply chain has dependencies.
The National Fragility Index is attempting to identify those dependencies before they become emergencies.
Why Active Pharmaceutical Ingredients Matter
One of the most important parts of pharmaceutical supply chains sits upstream of the finished medicine.
These are active pharmaceutical ingredients, or APIs.
An API is the component that provides the therapeutic effect of a medicine.
The United States can manufacture the finished dosage form of a drug while still relying on foreign production for the API or other critical inputs.
That means measuring only where the final pill, tablet or injectable is produced does not tell the whole story.
The upstream supply chain matters.
API production can be particularly vulnerable to concentration because manufacturing requires specialized facilities, technical expertise and regulatory compliance.
The API Innovation Center has previously focused on developing domestic production capabilities for critical APIs, including work supported by federal funding. Herald-Whig
The new fragility benchmark fits naturally into that strategy.
First identify the vulnerable products.
Then determine where the vulnerability exists.
Then direct investment toward the highest-risk points.
Broader Implications for U.S. Manufacturing
The U.S. pharmaceutical supply chain debate is increasingly becoming a manufacturing debate.
The United States can increase domestic production without necessarily eliminating supply-chain risk.
A new factory is only as resilient as the network supporting it.
If a domestic pharmaceutical plant depends on a single foreign supplier for a critical API, specialized chemical or manufacturing component, its location inside the United States does not make the entire supply chain domestic.
That is why supply-chain resilience requires a broader approach.
It can involve:
- Domestic API manufacturing
- Multiple qualified suppliers
- Strategic inventories
- Expanded manufacturing capacity
- Geographic diversification
- Modernized production technology
- Stronger supplier visibility
- Better data on upstream dependencies
The goal is not necessarily complete self-sufficiency.
The goal is fewer catastrophic single points of failure.
For more analysis of U.S. manufacturing, reshoring and industrial supply chains, explore The Tech Marketer’s manufacturing and supply-chain coverage.
Why This Matters to Hospitals and Pharmacies
Supply-chain fragility eventually becomes a healthcare problem.
Hospitals do not experience pharmaceutical supply chains as abstract networks.
They experience them as:
- Missing medicines
- Substitution decisions
- Emergency purchasing
- Higher procurement costs
- Inventory uncertainty
- Treatment delays
- Additional administrative work
Pharmacists may have to identify alternatives when a preferred medicine is unavailable.
Hospitals may have to ration scarce inventory.
Patients can ultimately feel the consequences.
That is why measuring fragility before an actual shortage occurs can have practical value.
A hospital cannot diversify a national pharmaceutical supply chain by itself.
But better national data can potentially help hospitals, manufacturers and policymakers understand where the greatest risks are concentrated.
The Economic Problem Behind Resilience
There is also an uncomfortable economic reality.
Resilience costs money.
Maintaining multiple suppliers costs more than relying on the cheapest supplier.
Keeping additional inventory costs more than operating with minimal stock.
Building redundant manufacturing capacity costs more than maximizing utilization at one factory.
Producing APIs domestically may cost more than importing them.
The market naturally rewards efficiency.
Supply-chain resilience rewards redundancy.
Those incentives can conflict.
That is why government policy is increasingly becoming part of the pharmaceutical manufacturing discussion.
If the market does not provide enough economic incentive to maintain strategically important production capacity, policymakers may decide that resilience itself has public value.
The new benchmark could help determine where that intervention makes the most sense.
Related History and Comparable Technologies
The pharmaceutical industry is not the only sector moving toward supply-chain risk measurement.
Semiconductor companies track geographic manufacturing concentration.
Energy companies monitor critical mineral dependencies.
Automakers map battery-material supply chains.
Defense contractors analyze strategic component availability.
The common theme is simple:
Visibility comes before resilience.
Companies cannot mitigate a dependency they cannot see.
Pharmaceutical supply chains are particularly complicated because the relevant information can stretch across multiple tiers.
A finished-drug manufacturer may know its direct suppliers while having less visibility into the suppliers behind those suppliers.
A disruption several steps upstream can therefore travel through the system before the final manufacturer recognizes the risk.
A benchmark that reaches down to individual drug product codes represents an attempt to make that complexity more manageable.
What Happens Next
The most important question is what policymakers and manufacturers do with the new benchmark.
Publishing a fragility score is useful.
Using it to change investment decisions is more important.
Several developments could follow.
1. Targeted domestic manufacturing
High-risk medicines could become candidates for new U.S. production capacity.
2. More API investment
Government and industry could focus more heavily on upstream ingredients rather than only finished medicines.
3. Procurement changes
Hospitals and government buyers could incorporate resilience metrics into purchasing decisions alongside price.
4. Strategic inventories
High-risk medicines could receive greater consideration for stockpiling or inventory-buffer programs.
5. Manufacturing diversification
Drug companies could seek additional suppliers or production sites for medicines identified as highly fragile.
6. Better supply-chain data
The benchmark could encourage manufacturers and policymakers to collect more detailed information about upstream dependencies.
The real test will be whether the National Fragility Index becomes a recurring decision-making tool rather than a one-time report.
Can Reshoring Fix the Problem?
Reshoring is part of the solution, but it is not a complete solution.
Moving production to the United States can reduce certain geopolitical and transportation risks.
But domestic production can still be concentrated.
If one U.S. factory produces most of a critical medicine, the supply chain can remain vulnerable to a fire, equipment failure, contamination event or quality shutdown.
The strongest supply chains combine domestic capacity with diversification.
That could mean several U.S. manufacturers.
It could mean U.S. production backed by qualified international suppliers.
It could mean multiple API sources.
It could mean strategic inventories.
The objective is not simply to move the factory.
It is to build a network that can absorb shocks.
The 550 Million Prescription Warning
The 550 million figure is therefore best understood as a signal.
It demonstrates that pharmaceutical supply-chain fragility is not confined to obscure medicines used by a handful of patients.
According to APIIC’s analysis, hundreds of millions of prescriptions in 2023 were associated with medicines classified as having High or Severe structural fragility. GlobeNewswire
That makes the issue large enough to matter at a national level.
It also suggests that pharmaceutical resilience cannot be treated solely as an emergency-preparedness problem.
It is an industrial-policy problem.
It is a manufacturing problem.
It is a procurement problem.
And ultimately, it is a healthcare-security problem.
Conclusion
The new U.S. pharmaceutical supply chain benchmark delivers an important warning: America’s medicine supply is not equally resilient across all products.
The API Innovation Center’s National Fragility Index found that more than 550 million prescriptions filled in 2023 involved medicines classified as having High or Severe supply-chain fragility. GlobeNewswire
That does not mean those prescriptions were unavailable.
It means a significant volume of medicine consumption is connected to supply chains with structural vulnerabilities.
The value of the new benchmark is that it attempts to turn those vulnerabilities into something measurable.
That could change the conversation around drug shortages.
Instead of waiting for a medicine to disappear from shelves, policymakers could identify fragile products in advance.
Instead of spreading manufacturing incentives broadly, governments could target the highest-risk medicines and upstream ingredients.
Instead of treating resilience as an emergency response, pharmaceutical companies could build it into their manufacturing and procurement strategies.
The United States does not necessarily need to manufacture every medicine domestically.
But it does need to know which medicines it cannot afford to lose.
The National Fragility Index is an important step toward answering that question.
FAQ
What is the U.S. pharmaceutical supply chain fragility benchmark?
The National Fragility Index, launched by the API Innovation Center, is a benchmark designed to measure and track structural fragility across U.S. pharmaceutical supply chains down to individual drug product codes. GlobeNewswire
How many prescriptions were associated with highly fragile medicines?
API Innovation Center’s analysis found that more than 550 million prescriptions filled in 2023 involved medicines classified as having High or Severe supply-chain fragility. GlobeNewswire
Does 550 million mean 550 million prescriptions were in shortage?
No. The figure measures prescriptions associated with medicines classified as having High or Severe structural supply-chain fragility. It should not be interpreted as 550 million prescriptions being unavailable or experiencing shortages.
What makes a pharmaceutical supply chain fragile?
Potential vulnerabilities include concentrated suppliers, limited manufacturing capacity, geographic concentration, dependence on overseas inputs, quality problems and insufficient alternative production capacity.
Why are active pharmaceutical ingredients important?
APIs are the components that provide a medicine’s therapeutic effect. A drug can be finished in the United States while still depending on foreign production of critical ingredients, meaning finished-product manufacturing alone does not capture the full supply-chain risk.
Can reshoring eliminate pharmaceutical supply-chain risk?
No. Domestic manufacturing can reduce certain foreign-supply risks, but a single domestic factory can still become a point of failure. Strong resilience generally requires diversification, adequate capacity, multiple suppliers and visibility across upstream tiers.
Why is the new benchmark important for U.S. manufacturing?
The benchmark could help policymakers and manufacturers identify which medicines and production networks have the greatest structural vulnerabilities, allowing investment to be targeted toward the highest-risk areas.
Sources & References
- API Innovation Center: API Innovation Center Launches the U.S.’ First Benchmark for Pharmaceutical Supply Chain Fragility
- API Innovation Center: Pharmaceutical Supply Chain Fragility
- API Innovation Center: The U.S. Pharmaceutical Supply Chain Fragility White Paper
- MarketMinute: API Innovation Center Launches the U.S.’ First Benchmark for Pharmaceutical Supply Chain Fragility
